About bosutinib
Tyrosine kinase inhibitor
Used for
- Treats Philadelphia chromosome-positive chronic myeloid leukemia in adults.
Usual adult dose
Usually 400 mg once daily with food for newly diagnosed disease, or 500 mg once daily for previously treated disease; dose may be adjusted.
Common side effects
- Diarrhea, nausea, vomiting, or abdominal pain
- Low blood cell counts
- Liver enzyme increases
- Rash, fatigue, or infection
Important warnings
- Can cause serious liver injury; liver tests are monitored.
- May cause low blood counts, fluid retention, or heart rhythm problems.
- Avoid grapefruit and grapefruit juice.
- Take with food; do not crush or split tablets.
Pregnancy
May harm an unborn baby. Effective contraception is recommended during treatment and for at least 2 weeks after the last dose.
Breastfeeding
Breastfeeding is not recommended during treatment and for at least 2 weeks after the last dose.
Interactions
- Strong CYP3A inhibitors can raise bosutinib levels; examples include clarithromycin and itraconazole.
- Strong CYP3A inducers can lower levels; examples include rifampin and carbamazepine.
- Acid-reducing medicines, including proton pump inhibitors, can lower bosutinib levels.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.